You are here: Industry Insights > Novartis

News List

Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities worldpharmanews
March 18, 2020
Novartis announced a broad set of measures to support the global response to the COVID-19 pandemic.
Orionis and Novartis enter drug discovery deal pharmaceutical-technology
March 09, 2020
Life sciences firm Orionis Biosciences has partnered with Novartis to discover and design new drugs for the treatment of a variety of diseases.
Novartis’ ‘life-changing’ Ilaris set for NHS funding pharmatimes
March 06, 2020
The NHS has revealed plans to fund Novartis’ Ilaris (canakinumab), for people with rare conditions causing repeated bouts of fever, joint pains and swelling.
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa worldpharmanews
March 05, 2020
The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV).
Novartis launches review of Beovu after safety concerns, says report europeanpharmaceuticalreview
March 04, 2020
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.
Novartis and NHS partner to improve manufacture of oligonucleotides europeanpharmaceuticalreview
January 14, 2020
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.
Iovance Biotherapeutics secures IOV-3001 licencing from Novartis pharmaceutical-technology
January 14, 2020
Iovance Biotherapeutics has secured the licence to develop and commercialise IOV-3001, an antibody cytokine engrafted protein, from Novartis.
Three more companies raise their US drug list prices europeanpharmaceuticalreview
January 07, 2020
Novartis, Merck and Allergan have joined numerous other pharmaceutical companies by increasing the price of certain drugs since the start of 2020.
Novartis Will Not Support Further Development of Fevipiprant for Asthma americanpharmaceuticalreview
December 18, 2019
Novartis announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily ...
Novartis’ fevipiprant fails to meet clinically relevant threshold in phase III asthma studies pharmaceutical-business-review
December 17, 2019
Novartis announced that its asthma treatment fevipiprant has failed to meet the clinically relevant threshold in Luster phase III studies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page